Return to homepagePandemic Pact

Sarilumab Clinical Trial in Hospitalized Adults With COVID-19 Presenting Cytokine Release Syndrome (SARICOR ASSAY).

Grant number: COVID-0013-2020

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $22,000

  • Funder

    Junta de Andalucia

  • Principal Investigator

    Julián de la Torre

  • Research Location

    Spain

  • Lead Research Institution

    Fundacion para la Investigacion Biomedica de Cordoba

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Clinical trials for disease management

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial.

Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial.

Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial.